| Metric | Value ($ M) |
|---|---|
| Revenue | 20.00 |
| Total Income | 20.00 |
| Expenditure | 46.55 |
| PBT | — |
| Net Profit | -24.21 |
| OPM | — |
| NPM | — |
| EPS | -0.45 |
Maze Therapeutics Reports Q1 2026 Financial Results
13 May 2026 · 13 May, 1:44 am
Summary
Maze Therapeutics reported its financial results for the first quarter ended March 31, 2026. The company highlighted positive topline data from the Phase 2 HORIZON trial of MZE829 in patients with broad AMKD. The company's cash, cash equivalents, and marketable securities were $528 million, including proceeds from a registered offering and a milestone payment. The company expects its cash runway to extend into 2029.
Key Highlights
- 1
Maze Therapeutics reported positive topline data from the Phase 2 HORIZON trial of MZE829 in patients with broad AMKD.
- 2
The company's cash, cash equivalents, and marketable securities totaled $528 million, inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026.
- 3
License revenue was $20.0 million for the quarter ended March 31, 2026, reflecting the achievement of a milestone pursuant to the exclusive license agreement with Shionogi & Co., Ltd.
- 4
Research & Development expenses increased to $34.1 million for the quarter ended March 31, 2026.
- 5
Net loss was $24.2 million, or $0.45 per share, for the quarter ended March 31, 2026.
- 6
Maze expects its cash runway to extend into 2029 based on its current business plan.
Management Comments
Jason Coloma
Ph.D.
“We continue to execute across our clinical pipeline in 2026, and with positive topline data reported from our Phase 2 HORIZON trial of MZE829 in broad AMKD in the first quarter, we are more confident than ever in our potential to harness the power of genetics to transform the lives of patients. Looking ahead to the rest of the year, we remain on track to initiate a Phase 2 trial of MZE782 in PKU around the middle of this year with topline data expected in 2027, and an additional Phase 2 study is expected to initiate in CKD in the second half of this year. We also look forward to reporting additional results from the HORIZON study in late 2026 or early 2027, and to advancing MZE829 into a pivotal trial in moderate AMKD patients without diabetes, including those with FSGS. With a strong balance sheet and expected cash runway into 2029, we continue to focus on clinical execution and pivotal study preparation.”
Informational and educational content only. Not investment advice.